ATOSSA THERAPEUTICS, INC. — Director's Dealing 2018

Jun 29, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ATOSSA GENETICS INC (ATOS)
CIK: 0001488039
Period of Report: 2018-06-27

Reporting Person: Guse Kyle (CFO, Gen Counsel and Secretary)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-06-27	Stock Option (right to buy)	$2.38	A	700000	Acquired	2028-06-27	Common Stock (700000)	Direct

Footnotes

F1: Twenty-five percent of the options have vested as of the grant date, 50% of the options will vest quarterly over two years, and the remaining 25% will vest upon achievement of certain milestones.